WHO Sounds Concern Over Acute Lack of Obesity Jabs
Fewer than a tenth of patients who could benefit from GLP-1 drugs including Wegovy have access to them, warns the World Health Organization as it releases its first recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to GLP-1 medication.
According to forecasts, over two billion could be obese by 2030 unless action is taken.
"Our latest guidance affirms that excess weight is a chronic disease that can be managed with comprehensive and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key obstacles to widespread access to the jabs that can aid individuals in losing considerable body mass, says the body.
Weight-Loss Drug Scarcity
Despite the present most favorable scenario, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, according to the health organization.
The advice calls on governments and firms to increase availability, by measures like voluntary licensing.
Exclusive production rights on a key compound – the core component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Drugs Function
The injections imitate a body's own hormone to reduce digestion speed, reduce hunger and increase feelings of fullness so users eat less.
People commonly begin shedding pounds after several weeks of starting on the once-weekly jabs.
Studies points to people may see weight return after a year of discontinuing the treatment, when their typical hunger resume.
Being overweight or obese raises your chance for developing diseases, like diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns people in all nations and was associated with over three and a half million fatalities worldwide in 2024, as per the health agency.
